NASDAQ · COGT
Cogent Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for COGT: Nov 6, 2026
Cogent Biosciences, Inc. Common Stock is estimated to report earnings on 11/06/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.57. The reported EPS for the same quarter last year was $-0.5.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.57 | $-0.52 | $-0.61 | 5 |
| Dec 2026 | $-0.59 | $-0.55 | $-0.64 | 5 |
| Mar 2027 | $-0.46 | $-0.25 | $-0.57 | 6 |
| Jun 2027 | $-0.38 | $-0.18 | $-0.51 | 6 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · Zacks · The Motley Fool- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- BNK Invest · Oct 13, 4:42 PM EDTCogent Biosciences Enters Oversold Territory (COGT)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- RTTNews · Sep 15, 10:27 AM EDTCogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027(RTTNews) – Cogent Biosciences Inc. (COGT) announced that the U.S. FDA has accepted its NDA for Bezuclastinib in adults with Advanced Systemic Mastocytosis and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2027.
- Zacks · Aug 13, 9:55 AM EDTCogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowCogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- RTTNews · Jul 1, 12:44 PM EDTCogent Submits NDA To FDA For Bezuclastinib In Treating Systemic Mastocytosis(RTTNews) – Cogent Biosciences Inc. (COGT), a biotechnology company, on Tuesday announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Bezuclastinib in treating advanced systemic mastocytosis.
- RTTNews · Jun 1, 3:39 AM EDTCogent Biosciences' Bezuclastinib Combo Doubles Progression-Free Survival In GIST(RTTNews) – Cogent Biosciences, Inc. (COGT) announced detailed Phase 3 results from its PEAK trial evaluating Bezuclastinib in combination with Sunitinib in patients with gastrointestinal stromal tumors previously treated with Imatnib.
- BNK Invest · May 18, 5:03 PM EDTRSI Alert: Cogent Biosciences (COGT) Now OversoldLegendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- RTTNews · Apr 2, 3:01 AM EDTCogent Submits NDA For Bezuclastinib In GIS Tumours After Non-AdvSM; Eyes NDA For AdvSM In H1,2026(RTTNews) – Cogent Biosciences, Inc. (COGT), a clinical-stage biotechnology company, announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Bezuclastinib in patients with Gastrointestinal Stromal Tumours (GI
- RTTNews · Apr 1, 10:32 AM EDTCogent Biosciences Stock Falls 6% After Submission Of New Drug Application For Bezuclastinib(RTTNews) – Stock of Cogent Biosciences, Inc. (COGT) is falling about 6 percent on Wednesday morning trading after the submission of its New Drug Application to the U.S. Food and Drug Administration for bezuclastinib in patients with Gastrointestinal Stromal Tumors.
- The Motley Fool · Mar 21, 7:33 PM EDTThis $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug LaunchRTW Investments added 4,124,755 Cogent Biosciences shares in the fourth quarter; the estimated trade size was $115.95 million.
- The Motley Fool · Mar 21, 6:43 PM EDTHigh-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest HoldingKynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million.
- The Motley Fool · Mar 20, 12:27 PM EDTBiotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026Boone Capital Management sold 945,042 shares of Cogent Biosciences in the fourth quarter.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Cogent Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.